Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2325-2335

  Stevenson, Andrew ^a   Roberts, Mark ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

aroA; Bordetella bronchiseptica; Live bacterial vector

Indexed keywords

ANTIGEN; GVB 120; LIVE VACCINE; TETANUS ANTIBODY; TETANUS TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM MUTANT; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; DRUG EFFECT; EXPRESSION VECTOR; FEMALE; GENE INACTIVATION; GENETIC RECOMBINATION; HETEROLOGOUS EXPRESSION; IMMUNIZATION; LOWER RESPIRATORY TRACT; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT INFECTION; UPPER RESPIRATORY TRACT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BORDETELLA BRONCHISEPTICA; BORDETELLA INFECTIONS; GENE EXPRESSION; GENETIC VECTORS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PHENOTYPE; TETANUS TOXIN; VACCINATION; VACCINES, ATTENUATED;

EID: 0037157269     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00118-4     Document Type: Article

References (49)

1. Biology of Bordetella bronchiseptica
2. Evaluation of Bordetella bronchiseptica vaccines in specific-pathogen-free piglets with bacterial cell surface antigens in enzyme-linked immunosorbent assay
3. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs
4. Epizootiological studies on porcine atrophic rhinitis. XV. Results of local immunization with a live Bordetella bronchiseptica strain in a large-scale pig herd affected by atrophic rhinitis
5. Efficacy of commercial vaccines for protecting guinea pigs against Bordetella bronchiseptica pneumonia
6. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis
7. Immunogenicity of killed Bordetella bronchiseptica vaccines in the mouse
8. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA
9. Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: Correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis
10. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines
11. Characterization of aromatic- and purine-dependent Salmonella typhimurium: Attention, persistence, and ability to induce protective immunity in BALB/c mice
12. Construction and characterization in vivo of Bordetella pertussis aroA mutants
13. Salmonella as carriers of heterologous antigens
14. Neisseria gonorrhoeae strain MS11 harbouring a mutation in gene aroA is attenuated and immunogenic
15. Immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG
16. Cross protective immunity conferred by a marker-free aroA mutant of Pasteurella multocida
17. Construction and vaccine potential of an aroA mutant of Pasteurella haemolytica
18. An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice
19. Virulence, persistence, and immunogenicity of Yersinia enterocolitica O:8 aroA mutants
20. Attenuation and vaccine potential of aroQ mutants of Corynebacterium pseudotuberculosis
21. Molecular characterization of the Aeromonas hydrophila aroA gene and potential use of an auxotrophic aroA mutant as a live attenuated vaccine
22. Bordetella bronchiseptica-mediated cytotoxicity to macrophages is dependent on bvg-regulated factors, including pertactin
23. Oral vaccination against tetanus: Comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters
24. PBBR1MCS: A broad-host-range cloning vector
25. Scanning electronmicroscopic studies of Bordetella bronchiseptica on the rabbit tracheal mucosa
26. Pregenomic comparative analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection
27. Protection against experimental Bordetella bronchiseptica infection in mice by active immunization with killed vaccine
28. Human Bordetella bronchiseptica infection related to contact with infected animals: Persistence of bacteria in host
29. Immunogenicity and safety of an attenuated Bordetella bronchiseptica vaccine in pigs
30. Prophylaxis of Bordetella bronchiseptica infection in guinea pigs by intranasal vaccination with live strain ts-S34
31. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity
32. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis
33. Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses
34. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: Development of a single-dose oral tetanus vaccine
35. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis
36. Neonatal pertussis
37. Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guerin producing a pertussis toxin-tetanus toxin hybrid protein
38. DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin
39. Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium
40. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum
41. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella
42. Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice
43. Cell surface-exposed tetanus toxin fragment C produced by recombinant Bacillus anthracis protects against tetanus toxin
44. Oral vaccination against tetanus: Comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters
45. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis
46. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C
47. Cattle immune responses to tetanus toxoid elicited by recombinant S. typhimurium vaccines or tetanus toxoid in alum or Freund's adjuvant
48. Neonatal tetanus in the world today
49. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines